Asston Pharmaceu

When is the next results date for Asston Pharmaceu?

Asston Pharmaceu is scheduled to announce its results on 14 November 2025.

Asston Pharmaceu is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Asston Pharmaceu?

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

Answer:<BR>The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28.10 Cr from 20.70 Cr. The book value per share adjusted increased to 17.6 from 11.45, reflecting the company's strengthening financial position.

Is Asston Pharmaceu overvalued or undervalued?

As of November 26, 2025, Asston Pharmaceu is considered overvalued with a PE ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35, despite outperforming the Sensex with a 1-week return of 17.65%.

As of 26 November 2025, Asston Pharmaceu's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Asston Pharmaceu's PE ratio is lower than that of Sun Pharma (37.53) and Divi's Lab (69.71), both categorized as expensive, while it is slightly higher than Cipla (22.59) and Dr. Reddy's Labs (18.02), which are viewed as attractive. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 17.65% compared to the Sensex's 0.50%, reinforcing the notion of overvaluation in the current market context.

Which are the latest news on Asston Pharmaceu?

Why is Asston Pharmaceuticals Ltd falling/rising?

As of 19-Apr, Asston Pharmaceuticals Ltd's stock price is rising to 79.30, up 5.17%. This increase is driven by strong relative performance, a recovery in investor sentiment after previous declines, and heightened investor participation.

As of 19-Apr, Asston Pharmaceuticals Ltd's stock price is rising, currently at 79.30, reflecting an increase of 3.9 or 5.17%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 5% today, indicating strong relative performance. Additionally, there has been a trend reversal as the stock gained after two consecutive days of decline, suggesting a recovery in investor sentiment.<BR><BR>The stock opened with a significant gain of 4.77% today and reached an intraday high of Rs 81.5, which is an increase of 8.09%. Furthermore, there has been a notable rise in investor participation, with delivery volume on April 16 increasing by 782.35% compared to the 5-day average, indicating heightened interest from investors. <BR><BR>Despite these positive indicators, the stock has experienced volatility, as it did not trade on one day out of the last 20 days. However, the overall performance today reflects a positive shift in momentum for Asston Pharmaceuticals Ltd.